HK1049958A1 - 在激活的t淋巴細胞內通過利巴韋林和其類似物調整th1/th2細胞素的表達以治療hcv感染 - Google Patents

在激活的t淋巴細胞內通過利巴韋林和其類似物調整th1/th2細胞素的表達以治療hcv感染

Info

Publication number
HK1049958A1
HK1049958A1 HK03101779.2A HK03101779A HK1049958A1 HK 1049958 A1 HK1049958 A1 HK 1049958A1 HK 03101779 A HK03101779 A HK 03101779A HK 1049958 A1 HK1049958 A1 HK 1049958A1
Authority
HK
Hong Kong
Prior art keywords
ribavirin
actived
lymphocytes
modulation
cytokine expression
Prior art date
Application number
HK03101779.2A
Other languages
English (en)
Inventor
Tam Robert
Ramasamy Kandsamy
Averett Devron
Original Assignee
Ribapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Ribapharm Inc filed Critical Ribapharm Inc
Publication of HK1049958A1 publication Critical patent/HK1049958A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052Imidazole radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HK03101779.2A 1996-01-23 2003-03-12 在激活的t淋巴細胞內通過利巴韋林和其類似物調整th1/th2細胞素的表達以治療hcv感染 HK1049958A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497A 1997-01-14 1997-01-14

Publications (1)

Publication Number Publication Date
HK1049958A1 true HK1049958A1 (zh) 2003-06-06

Family

ID=26712783

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101779.2A HK1049958A1 (zh) 1996-01-23 2003-03-12 在激活的t淋巴細胞內通過利巴韋林和其類似物調整th1/th2細胞素的表達以治療hcv感染

Country Status (3)

Country Link
EP (1) EP1240899A3 (zh)
JP (3) JP3416147B2 (zh)
HK (1) HK1049958A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104070A1 (en) * 2006-03-14 2007-09-20 Wholesome Biopharm Pty Ltd Method and composition for treating allergic diseases
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2013337663A1 (en) 2012-11-02 2015-06-11 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
JP7109056B2 (ja) 2018-05-17 2022-07-29 静岡県公立大学法人 S-icaリボシルホモシステインの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135669A1 (en) * 1994-11-10 1996-05-11 Nils O. Johannesson Ribavirin as hepato (liver) protecting agent
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
EP1240899A2 (en) 2002-09-18
JP2004035537A (ja) 2004-02-05
JP2008133293A (ja) 2008-06-12
EP1240899A3 (en) 2004-05-19
JP3416147B2 (ja) 2003-06-16

Similar Documents

Publication Publication Date Title
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
HU228218B1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
ID21694A (id) Metode-metode dan komposisi-komposisi untuk mengurangi gurat-gurat halus dan kerut-kerut pada kulit
ZA947138B (en) Skin care method and composition
HUP9900681A3 (en) Use of ribavirin for producing compositions to influence on th1 and th2 response
ZA939677B (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
HK1049958A1 (zh) 在激活的t淋巴細胞內通過利巴韋林和其類似物調整th1/th2細胞素的表達以治療hcv感染
GB2275029B (en) Improvements in and relating to wheelchairs
EP0739899A3 (en) Oligoribonucleotide derivatives and their use as antiviral drugs
GB9120003D0 (en) Improvements in and relating to current devices
AU9034291A (en) Derivates of the human parathormone fragment (1-37) in the amide or ethylamide form as active substance
EP0267684A3 (en) Human leukocyte interferon composition and skin treatment
EP0656116A4 (en) METHOD FOR MONITORING THE EFFECTIVENESS OF INTERFERON THERAPY ON HEPATITIS-C INFECTED INDIVIDURES.
ZA9010337B (en) Fibroblast growth factor for use in the prevention and treatment of viral infections
GB9127571D0 (en) Improvements in and relating to proximity switches
Zhang Effect of ribavirin on acute and persistent human coronavirus infection, in vitro.
GB2311218B (en) Improvements in and relating to baths
GB9609789D0 (en) Improvements in and relating to slew devices
GB8918519D0 (en) Improvements to limb braces and immobilisers
GB9224227D0 (en) Improvements in and relating to bandsaws
IT1255469B (it) Uso della n-acetil-cisteina nella prevenzione e nel trattamento della discinesia tardiva
HUT65100A (en) Sporting device for moving and strengthening of human muscles
KR950701009A (ko) 복합체 및 그 사용방법(composite body and its use)